4.7 Review

Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer

Journal

Publisher

MDPI
DOI: 10.3390/ijms24044154

Keywords

prostate cancer; drug repurposing; non-cancer drugs; approved drugs

Ask authors/readers for more resources

Prostate cancer is the second most common cancer in men worldwide and a leading cause of death. Standard treatments face issues like side effects and resistance, highlighting the need for drugs that can fill these gaps. This review compiles drugs that can be repurposed for prostate cancer treatment, categorizing them based on their pharmacotherapeutic groups and discussing their mechanisms of action.
Worldwide, prostate cancer (PC) is the second most frequent cancer among men and the fifth leading cause of death; moreover, standard treatments for PC have several issues, such as side effects and mechanisms of resistance. Thus, it is urgent to find drugs that can fill these gaps, and instead of developing new molecules requiring high financial and time investments, it would be useful to select non-cancer approved drugs that have mechanisms of action that could help in PC treatment, a process known as repurposing drugs. In this review article, drugs that have potential pharmacological efficacy are compiled to be repurposed for PC treatment. Thus, these drugs will be presented in the form of pharmacotherapeutic groups, such as antidyslipidemic drugs, antidiabetic drugs, antiparasitic drugs, antiarrhythmic drugs, anti-inflammatory drugs, antibacterial drugs, antiviral drugs, antidepressant drugs, antihypertensive drugs, antifungal drugs, immunosuppressant drugs, antipsychotic drugs, antiepileptic and anticonvulsant drugs, bisphosphonates and drugs for alcoholism, among others, and we will discuss their mechanisms of action in PC treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available